pan-European Management of Biological toxin incidents through standaRdisAtion initiatives for Crisis response Enhancement
Acronym
EMBRACE
Description of the granted funding
Biotoxins pose significant challenges to current crisis management approaches. Existing concepts of operation, derived from Chemical, Biological, Radiological and Nuclear doctrines, and Union Civil Protection Mechanism initiatives, do not address the distinctive and highly complex attributes of a biotoxin crisis. EMBRACE aims to improve Europe’s capacity to respond effectively to biotoxin incidents.
We will consolidate and apply scientific and clinical knowledge of biotoxins to revise response protocols and deliver innovative solutions specifically tailored to address gaps and needs identified in current provision. Highlights include analysis of biotoxins not previously addressed in this context, risk-based recommendations for PPE and novel decontaminants, in vitro studies to identify human biomarkers of exposure, novel samplers, portable biosensors and field diagnostics devices, and software tools to assist responders in biothreat risk assessment. To ensure intersectoral and cross-border interoperability of these solutions and successful commercialisation of our exploitable assets, we will prioritise a carefully planned standardisation and valorisation programme. EMBRACE will engage with existing initiatives and projects to create a vibrant biotoxin knowledge network; a multi-sectoral community of stakeholders, on the basis of which a sustainable Biotoxin Task Force will be established as a source of expertise and guidance on biotoxin incidents both for EMBRACE and the wider community. The network of stakeholders and EMBRACE’s ambitious programme of scientific, technological, and operational advances will be supported by the creation of a biotoxin reference and stakeholder hub designed to facilitate knowledge exchange and provide users with direct access to widely distributed and expertise. Finally, EMBRACE’s innovative sustainability strategy will ensure that its solutions and the biotoxin community continue to thrive beyond the duration of the project.
Show moreStarting year
2024
End year
2027
Granted funding
SAITAMA MEDICAL UNIVERSITY EDUCATIONAL CORPORATION (JP)
269 375 €
Participant
URAD PRE NORMALIZACIU, METROLOGIU A SKUSOBNICTVO SLOVENSKEJ REPUBLIKY (SK)
91 250 €
Participant
BIOXHALE LTD (UK)
Participant
MOBILITY ION TECHNOLOGIES SL (ES)
277 125 €
Participant
IANUS CONSULTING LTD (CY)
382 500 €
Participant
CESKA AGENTURA PRO STANDARDIZACI (CZ)
93 500 €
Participant
DISASTER COMPETENCE NETWORK AUSTRIA (AT)
446 620 €
Participant
RESILIENCE ADVISORS LTD (UK)
Participant
TECHNOLOGICKA PLATFORMA ENERGETICKABEZPECNOST CR ZS (CZ)
180 000 €
Participant
POMPIERS DE L'URGENCE INTERNATIONALE (FR)
246 750 €
Participant
Airsense Analytics GmbH (DE)
331 250 €
Participant
PROMETECH BV (NL)
510 000 €
Participant
OSTERREICHISCHES ROTES KREUZ (AT)
323 625 €
Participant
TELESTO TECHNOLOGIES PLIROFORIKIS KAI EPIKOINONION EPE (EL)
763 750 €
Coordinator
THE LISBON COUNCIL FOR ECONOMIC COMPETITIVENESS ASBL (BE)
234 375 €
Participant
MEDIZINISCHE UNIVERSITAT GRAZ (AT)
603 125 €
Participant
BIOTALENTUM TUDASFEJLESZTO KFT (HU)
279 750 €
Participant
Amount granted
5 620 216 €
Funder
European Union
Funding instrument
HORIZON Research and Innovation Actions
Framework programme
Horizon Europe (HORIZON)
Call
Programme part
Civil Security for Society (11700 Disaster-Resilient Societies (11701 )
Topic
Operability and standardisation in response to biological toxin incidents (HORIZON-CL3-2023-DRS-01-03Call ID
HORIZON-CL3-2023-DRS-01 Other information
Funding decision number
101168322